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In vitro  test  methods  may  be  vital  in  understanding  tobacco  smoke,  the  main  toxicants  responsible  for
adverse  health  effects,  and  elucidating  disease  mechanisms.  There  is  a variety  of  ‘whole  smoke’  exposure
systems  available  for  the  generation,  dilution  and delivery  of  tobacco  smoke  in  vitro;  these  systems
can  be  procured  commercially  from  well-known  suppliers  or can be bespoke  set-ups.  These  exposure
technologies  aim to  ensure  that  there  are  limited  changes  in the  tobacco  smoke  aerosol  from generation
to  exposure.  As  the  smoke  aerosol  is freshly  generated,  interactions  in  the smoke  fractions  are  captured
in any  subsequent  in  vitro  analysis.  Of the  commercially  available  systems,  some  have  been  characterised
more than  others  in  terms  of  published  scientiﬁc  literature  and  developed  biological  endpoints.  Others
are relatively  new  to the  scientiﬁc  ﬁeld  and are  still  establishing  their  presence.  In  addition,  bespoke
systems  are  widely  used  and  offer a more  ﬂexible  approach  to  the challenges  of tobacco  smoke  exposure.
In this  review,  the authors  present  a summary  of the  major  tobacco  smoke  exposure  systems  available
and critically  review  their  function,  set-up  and  application  for in  vitro  exposure  scenarios.  All whole
smoke  exposure  systems  have  beneﬁts  and  limitations,  often  making  it difﬁcult  to  make  comparisons
between  set-ups  and  the  data  obtained  from  such  diverse  systems.  This  is  where exposure  and  dose
measurements  can  add value  and  may  be  able  to  provide  a platform  on which  comparisons  can  be made.
The  measurement  of smoke  dose,  as  an  emerging  ﬁeld  of  research,  is  therefore  also  discussed  and  how
it  may  provide  valuable  and  additional  data  to support  existing  whole  smoke  exposure  set-ups  and  aid
validation  efforts.© 2013 Elsevier GmbH. All rights reserved.
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. Introduction
In order to understand the various physiological and phys-
cochemical processes associated with tobacco consumption,
specially disease associations, we must ﬁrst understand the com-
lex dynamics of tobacco smoke, which may  allow the precursors
nd mechanisms responsible for adverse health effects to be
scertained. The approximate composition of mainstream tobacco
moke is relatively well deﬁned, due to decades of research and
dvances in analytical techniques (Borgerding and Klus, 2005; Liu
t al., 2011; Talhout et al., 2011). Tobacco smoke is a complex and
ynamic aerosol consisting of thousands of chemicals, the most
ecent estimate is 5600 individual smoke components (Perfetti and
odgman, 2011) of which approximately 158 have toxicological
roperties – termed tobacco smoke toxicants (Fowles and Dybing,
003). Distributed between the particulate and gaseous fractions
nd sometimes present in both are chemicals known to be asso-
iated with various smoking related diseases. For example; the
ldehydes (formaldehyde, acrolein, acetaldehyde) are found in the
aseous phase (Baker, 2006) of cigarette smoke and are associ-
ted with chronic obstructive pulmonary disease (COPD) and lung
oxicity (IARC, 1985; Barnes, 2003; IARC, 2006). Polycyclic aro-
atic hydrocarbons (PAHs), tobacco speciﬁc nitrosamines (TSNAs),
rsenic, cadmium and chromium are found in the particulate phase
f cigarette smoke and can be linked with various cancers (IARC,
990, 1993; Hoffmann and Hoffmann, 1997; Levitz et al., 2004).
Tobacco smoke assessment in vitro has traditionally focused
n the particulate phase captured on a Cambridge ﬁlter pad and
luted in DMSO (Crooks et al., 2013) or bubbled through cell cul-
ure media or PBS (Andreoli et al., 2003). Cell cultures are then
xposed under submerged conditions to the particulate phase.
nfortunately, particulate based exposure scenarios do not take
nto account the vapour phase of cigarette smoke, or the asso-
iated interactions between the particulate and vapour phases.
ubmerged culture conditions and particulate-based exposures do
ot represent physiologically that of mainstream tobacco smoke
xposure in the human lung. Furthermore, separating smoke frac-
ions in this way could lead to alterations and chemical changes
hat may  not be representative of the whole smoke aerosol. In order
o address these challenges, whole smoke exposure systems have
een developed. Whole smoke exposure systems offer many tech-
ical challenges, but represent a more physiologically relevant test
ystem that captures the full interactions of both the particulate and
apour phase together (Fukano et al., 2004). An additional advan-
age of these systems is that a multitude of different cell cultures
an be exposed at the air–liquid interface (ALI) to whole smoke,
etter simulating human exposure.
There are a diverse range of whole smoke exposure systems
vailable ranging from commercial set-ups (Aufderheide and Mohr,
999; Phillips et al., 2005; Scian et al., 2009a; Okuwa et al., 2010) to
espoke in-house designed and developed exposure systems (St-
aurent et al., 2009; Muller et al., 2011; Zhang et al., 2011; Gualerzi
t al., 2012). Irrespective of origin, these systems generally have
n common two main components: (1) a smoking machine, which
enerates, dilutes and delivers cigarette smoke; (2) an exposure
hamber which houses the associated biological system often (but
ot always) at the ALI. The amount of smoke delivered within these
n vitro exposure systems can be presented in many ways, often . . . .  . . .  . . . . .  .  . . .  .  . . . . .  . .  . . . . . . .  . . . . .  . . .  .  . . .  . . .  .  .  . . . . .  .  .  .  .  .  . . . . . . . . . .  .  . .  .  . 1192
dependent upon the machine used. Delivered smoke can be pre-
sented either as a ratio of smoke to air, a ﬂow rate of mixing air
applied to the smoke dilutor, as a percentage of smoke, as smoke
fraction, or as cigarette puff number. As there is no consensus on
how in vitro smoke data should be presented, this makes compar-
isons of research difﬁcult. What is more relevant and is becoming
increasingly important in the ﬁeld of in vitro whole smoke assess-
ment is dosimetry: i.e. how to quantify the smoke dose to which
the cells are directly exposed. As there is not a consistent approach
to whole smoke exposure, with a variety of systems and laboratory
set-ups being used, dose tools could play an important role and
bridge the gap between technologies; not only in the measurement
of actual cellular dose but also in the characterisation and validation
of these systems. Furthermore, utilising dose tools will add strength
to the resulting in vitro data and potentially allow cross-platform
comparisons to be made, where currently they cannot.
2. Whole smoke exposure systems
The development of whole smoke exposure systems has been
driven by the fact that traditional smoke exposure techniques are
based on the particulate phase of cigarette smoke and omit the
vapour phase and semi-volatiles from any subsequent analysis.
Whole smoke exposure systems offer the advantage that all phases
of smoke can be analysed together or independently depend-
ing on the experimental set-up. This has allowed researchers to
tailor their experiments to investigate both phases of tobacco
smoke, yielding useful information. There are a variety of whole
smoke systems available and the majority of these systems can
also be used to deliver individual aerosols or other complex
aerosol mixtures to cell cultures. Consequently these systems can
have applications outside the tobacco industry, however limited
information and fewer guidelines exist for the assessment of air-
borne chemicals in vitro (Costa, 2008; Bakand and Hayes, 2010).
Examples of commercially available systems include (but are
not limited to): the Borgwaldt RM20S (Borgwaldt KC, Hamburg,
Germany); the Burghart MSB-01 (Burghart Tabaktechnik Wedel,
Germany); and the Vitrocell® VC 10 (Vitrocell® Systems, Waldkirch,
Germany). Commercially available exposure chambers or mod-
ules which are linked with these machines include those supplied
by British American Tobacco (Curbridge Engineering, Southamp-
ton, UK); CULTEX® (CULTEX® Laboratories Hannover, Germany);
and Vitrocell® (Vitrocell® Systems, Waldkirch, Germany). There
are pronounced similarities between a number of CULTEX® and
Vitrocell® exposure modules, and this is due to their shared
inception. However, after seven years of scientiﬁc, technical and
commercial cooperation (1999–2006) on the development of
approaches to in vitro toxicity testing, the working team split
and formed what is today known as the CULTEX® and Vitrocell®
groups. This explains similarities and compatibilities between the
two systems as well as the diversity in more recent developments.
In addition to commercially available systems some examples of
bespoke systems are also discussed.
A summary of the commercially available and published in vitro
exposure smoking machines and exposure chambers can be found
in Tables 1 and 2 respectively.
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Table 1
Comparison of the technical speciﬁcation of the 3 main commercially available smoking machines. All measurements made by authors () and information obtained from
technical support and commercially available sources (*), unless otherwise referenced.
Smoking machine Borgwaldt RM20S Smoking
Machine
Burghart MSB-01 Mimic Smoker Vitrocell VC 10 Smoking Robot
Dimensions (L × D × H) 2.4 m × 0.8 m × 1.3 m 0.75 m × 0.35 m × 0.48 m* 1.5 m × 0.8 m × 0.85 m
Footprint Free standing (2 m2 footprint) Bench top (0.8 m2 footprint)* Bench top (1.2 m2 footprint)
Dilution system Syringe based independent
dilution system (capable of 8
dilutions) (Adamson et al., 2011)
Syringe based independent
dilution system (capable of 5
dilutions) (Scian et al., 2009a)
Continuous ﬂow dilution bar
(capable of 4 dilutions) (Okuwa
et al., 2010)
Dilution  range 1:2–1:4000 (smoke:air, v/v) (Kaur
et al., 2010)
1:1–1:150 (smoke:air, v/v) (Scian
et al., 2009a)
Airﬂow 0–12 l/min and vacuum
rate 5–200 ml/min
Throughput 8 chambers with 3, 6, 8
inserts/chamber
96 well format* 4 modules with 3, 4
inserts/module; 96 or 24 well plate
manifold,*
Computer controller Integrated computer Integrated computer* Requires PC
Smoking regime ISO and HCI* ISO, HCI and multi-smoking
regimes*
ISO, HCI and bespoke smoking
regimes (Li et al., 2012)
Tubing  length to exposure device ∼3.4 m ∼1 m* ∼1.4 m
Exposure chamber/module Predominantly the British
American Tobacco Exposure
chamber – manufactured by
Integrated multi-well 24 and 96
plates
Vitrocell® or Cultex® exposure
modules
2
i
t
b
l
m
u
c
H
u
e
s
‘
a
C
a
s
l
c
e
M
d
T
C
tCurbridge Engineering
Time  taken from puff to exposure ∼15–24 s (depending on dilution)
Air ﬂow controller Integrated 
.1. Bespoke systems
Bespoke exposure set-ups tend to be utilised by those involved
n fundamental tobacco smoke research. Although there is lit-
le room for comparison between commercially available and
espoke systems, these one-off-a-kind set-ups offer the beneﬁt of
ower cost, smaller footprint, reduced complexity and often ease of
aintenance. There are a wide range of bespoke designs and set-
ps ranging in sophistication and offer unique and often simple
igarette smoke generation, dilution and exposure characteristics.
ere we explore a few examples of how bespoke systems can be
sed to generate meaningful biological data.
St-Laurent et al. (2009) described one such system for the ALI
xposure of isolated rat bronchial epithelial cells to the mainstream
moke from two cigarettes. The exposure system consisted of a
hermetic chamber with two ventilation holes’ large enough to
ccommodate a cell culture plate, and installed with a small fan.
ells were exposed to smoke twice daily for three consecutive days
nd cell supernatants were obtained at baseline and day three for
ubsequent mediator (MCP-1, IL-10, VEGF) assessment by enzyme-
inked immunosorbent assay. The ALI results were also compared to
ells exposed to cigarette smoke extract (CSE) under a submerged
xposure condition. Analysis of the ALI results demonstrated that
CP-1 release was inhibited compared to the CSE model, IL-10 pro-
uction was reduced, and VEGF showed no difference in production
able 2
omparison of the technical speciﬁcation of 4 different commercially available exposure
echnical support and commercially available sources (*), unless otherwise referenced.
Exposure chamber Curbridge Engineering
(British American Tobacco)
Cultex® exp
Approximate dimensions (D × W × H) 12 cm × 9 cm 10 cm × 16 c
Approximate weight 0.65 kg 2.5 kg* 
Material Transparent Perspex Polished sta
glass*
Capacity 3 × 24 mm ø inserts 3 × 24 mm ø
6  × 12 mm ø inserts 3 × 12 mm ø
8  × 6.5 mm ø inserts 3 × 35 mm ø
3  × 30 mm ø Petri dishes
1  × 85 mm ø Petri dish
Chamber smoke delivery Sedimentation, Brownian
motion, gravitation*
Guided via f
metal inlet t∼6 s (Scian et al., 2009a) ∼8 s
Integrated Additional equipment required
between the two models. The authors concluded that the CSE and
ALI models modulated bronchial epithelial cell mediator produc-
tion differently, demonstrating that the model used can inﬂuence
the data obtained (St-Laurent et al., 2009). Additionally, this sug-
gests that varying cellular responses are observed when using
different tobacco smoke fractions, indicating that different smoke
fractions have independent roles in mediating tissue responses.
In another example, an exposure chamber (Phillips et al., 2005)
was paired with a simple in-house cigarette smoke generator to
assess the effect of smoke on human (healthy smokers and individ-
uals with COPD) brushed bronchial epithelial cells and their innate
immune response to Moraxella catarrhalis infection (Zhang et al.,
2011). One cigarette was combusted using a pump and smoke was
drawn into a 1000 ml  ﬂask for a 10 min  exposure to cells housed
at the ALI. The results demonstrated that tobacco smoke increased
bacterial load but decreased prostaglandin E2 (PGE2) production;
PGE2 having been shown to exert immunomodulatory functions.
The authors commented that the results help to clarify the role of
PGE2 in mucosal innate immunity of COPD patients (Zhang et al.,
2011).
In a ﬁnal example, a cigarette, syringe and a sterile ﬂask were
connected by tubes in a T-shape via a tap at the connection point
(Gualerzi et al., 2012) to create an uncomplicated yet unique set-
up. The sterile ﬂask contained keratinised oral mucosa explants
from healthy non-smoking woman, in a semi-immersed condition
 chambers. All measurements made by authors () and information obtained from
osure module Cultex® radial ﬂow system
(RFS)
Vitrocell modules
(PT-CF/Ames)
m × 13 cm*  35 cm × 24 cm × 20 cm 10 cm × 16 cm × 13 cm
11.5 kg 4.5 kg
inless steel and Polished stainless steel and
glass*
Polished stainless
steel/glass and aluminium*
 inserts* 3 × 24 mm ø inserts* 3 or 4 × 24 mm ø inserts*
 inserts* 3 × 12 mm ø inserts* 3 or 4 × 12 mm ø inserts*
 Petri dishes* 3 × 6.5 mm ø inserts* 3 × 35 mm ø Petri dishes*
Petri dishes*
unnel-shaped
ube (trumpet)*
Sedimentation, diffusion,
electrical forces and
inertial impaction
(Aufderheide et al., 2011)
Direct exposure technology
(trumpet)*
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Fig. 1. A Borgwaldt RM20S smoking machine with 8 syringes. (A) Cigarette smoke
generator. (Bi) A syringe based dilution system with 4 syringes. An additional 4
syringe unit is available from Borgwaldt KC GmbH, Hamburg Germany (Bii). (C)
Air  ﬂow controller. (D) Cell culture media maintained at 37 ◦C feeding exposure
chambers with fresh cell culture medium and (E) a BAT exposure chamber housed
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o better represent the physiological condition of the oral cavity.
 single cigarette was smoked for 6 min  by ‘inhaling’ through the
yringe, turning the tap to exhale the smoke to the ﬂask, then
etachment of the ﬂask to allow the outﬂow of smoke and air
ecirculation; the whole cycle being repeated until the cigarette
as smoked. Post-exposure, biomarkers of intracellular adhesion
ere evaluated by histochemical and immunoﬂuorescence anal-
sis. The results obtained suggested that the ﬁrst response to
igarette smoke came from the basal/suprabasal layers of the oral
pithelium, with an overexpression of keratin protein (K14) as early
s 3 h after smoke exposure. Furthermore, this set-up maintained
he 3D arrangement of the human mucosa and allowed a quasi-
eplication of the inhalation/exhalation cycle (Gualerzi et al., 2012).
.2. Borgwaldt
The Borgwaldt RM20S (Borgwaldt KC GmbH, Hamburg,
ermany) is a rotary style, syringe smoking machine, capable of
moking up to eight cigarettes simultaneously (Fig. 1) without
ross-cigarette contamination. The combination of smoking allows
ither eight different cigarettes to be assessed using one dilution
r one cigarette type at eight dilutions. Thus the RM20S smok-
ng machine can be used for both product assessment purposes
nd fundamental research. Smoke is generated via a syringe which
raws a puff from the cigarette ﬁrst, sequentially followed by a puff
f ﬁltered air to create the required dilution, expressed as a ratio of
moke in air (1:X, volume:volume). Larger dilutions require a serial
ilution process. Diluted smoke is exhausted from the syringe at
.8 l/min into the exposure chamber. Each syringe is attached to an
ndividual exposure chamber which ensures that no cross-cigarette
r cross-dilution contamination can occur. Dilution of smoke and
ellular exposure can take anywhere between 12 and 24 s depend-
ng on dilution.
Although not supplied together, and designed to be interchange-
ble, the Borgwaldt RM20S has almost exclusively been paired with
he British American Tobacco (BAT) exposure chamber manufac-
ured by Curbridge Engineering (Southampton, UK) (Fig. 2). This
peciﬁc combination has been documented through a series of
n vitro development and machine characterisation papers (Phillips
t al., 2005; Maunders et al., 2007; Thorne et al., 2009; Kaur et al.,
010; Adamson et al., 2011, 2013a).
Phillips et al. (2005) ﬁrst investigated cellular responses
n bronchial epithelial NCI-H292 cells exposed to cigarette
moke, using the RM20S and BAT exposure chamber. This study
ig. 2. British American Tobacco’s exposure chamber manufactured by Curbridge Engin
xposure chamber introduces the test aerosol through a single gas inlet which creates a
nsures  uniform cellular exposure.at 37 ◦C, attached to the smoke diluter and culture media (modiﬁed from Adamson
et  al., 2011).
demonstrated cytotoxicity, particulate deposition, mRNA
(MUC5AC) and protein expression (Interleukin 6, 8, GRO-
and matrix metalloproteinase 1) in response to tobacco smoke
exposure. Maunders et al. (2007) followed up this work using
primary human lung bronchial epithelial cells focusing on gene
expression changes following smoke exposure using Affymetrix
and microarray technology. The results were consistent with pre-
viously reported in vitro and in vivo studies on smoke toxicity, such
as increased epithelial permeability, antioxidant responses and
MAPK pathways (Hackett et al., 2011). Maunders et al. (2007) also
concluded that the down regulated responses in cell adhesion may
provide a possible mechanism for smoke induced permeability and
have implications in the development of various tobacco smoke
induced diseases.
Initial characterisation of the RM20S was  conducted by Kaur
et al. (2010) who compared two  RM20S machines in different
eering (Hampshire, UK) and a schematic cross-section (Thorne et al., 2009). The
 passive, sedimentary exposure scenario. A symmetrical smoke distribution plate
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Fig. 3. Schematic cross-section of the Vitrocell® VC 10 Smoking Robot. (A) Smoking robot carousel and side stream chimney, where cigarettes are loaded and smoked. (B)
Piston/syringe which draws and delivers ISO (35 ml)  or HCI (55 ml) mainstream cigarette smoke. (C) Air jets add continuous diluting air perpendicular to the mainstream
smoke in the range of 0.2–12 l/min; rates are set and maintained by mass ﬂow controllers. (D) Dilution, transit and delivery of whole smoke occurs in the dilution bar.
(E)  Isolated cell culture inserts are supported and exposed to diluted whole smoke at the ALI in a module which docks under the dilution system. (F) Negative pressure is
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opplied  to the module which draws the diluted smoke from the dilution bar, into th
ow  rates, applied via a vacuum per well can vary depending on exposure conditio
bserved. (G) Due to continuous diluting airﬂow, smoke remaining in the dilution s
eographical locations, Canada and the UK. Using a hydrocar-
on analyser, a 10% methane gas standard, syringe dilution and
recision across the two locations were assessed. The results
emonstrated that although there was syringe variability, both
achines in different locations were similar in performance (<10%
elative standard deviation). Further characterisation was con-
ucted by Adamson et al. (2011) who described losses in the
ystem equivalent to those reported for the Burghart MSB-01 (Scian
t al., 2009a). By using an electromobility spectrometer (DMS500
ambustion, UK) at various positions along the system (post-puff,
re-chamber and post-chamber) they were able to demonstrate
48% loss of mainstream smoke before cellular exposure and ∼16%
eposition within the chamber.
One of the main limitations of the RM20S exposure system and
ssociated chamber combination is that to date it has been almost
xclusively used by British American Tobacco making direct com-
arisons between other studies difﬁcult.
.3. Burghart
The Burghart Mimic  Smoker MSB-01 (Burghart Tabaktechnik,
edel, Germany) differs from other commercially available smoke
xposure systems in that it has an integrated multi-plate format,
esigned for high throughput in vitro experimentation. The expo-
ure plate (96 microwell format) is integral to the exposure system
nd therefore offers a simplistic approach free from the complica-
ion of an associated independent exposure module. The MSB-01
moking machine is designed with independent syringes which
nable a range of cigarettes or doses to be assessed. The syringes
ave a dilution capability up to 1:150 (smoke:air, v:v). A smoke dis-
ribution plate or manifold provides a consistent exposure via two
orts across the multiwell plate. Cigarette puff to exposure takes
pproximately 6 s.
Characterisation of the MSB-01 was conducted by Scian et al.
2009a,b) including particulate deposition in the multiwell plate,
moke loss measurement, particle size, and cellular viabilities.
eposition on the exposure microwell plate was determined by
ptical ﬂuorescence (370 nm)  of particulate matter dissolved inule via the ‘trumpet’ inlets and out of the module through the exhaust. Volumetric
 5 to 200 ml/min, however a consistent ﬂow rate per well of 5 ml/min is normally
 transits to exhaust away from the module (modiﬁed from Adamson et al., 2013b).
DMSO, whilst smoke loss measurements were determined by par-
ticulate capture at various points in the system. Bronchial epithelial
BEAS-2B cells were used to assess cytotoxicity following smoke
exposure. The information accumulated has resulted in a good
understanding of how the MSB-01 performs with regards to smoke
losses, deposition and dilution reproducibility. Furthermore, anal-
ysis of cigarette smoke chemistry within the system has helped
in the understanding of how the machine delivers smoke and the
effects of dilution on particle size and distribution. Reported loses
in this system preceding exposure were similar to those identiﬁed
for the Borgwaldt RM20S, between 40% and 50% (Adamson et al.,
2011; Scian et al., 2009b).
Compared to other smoke exposure machines, the MSB-01 is
a higher throughput option. However, one potential drawback of
this technology is that cells are not supported at the ALI, which
ultimately limits the MSB-01 for use in simplistic cellular studies.
There are also set-up implications such as a smoke collection cham-
ber and a ‘mixing’ bag which may  artiﬁcially age smoke (Scian et al.,
2009a).
2.4. Vitrocell® Systems
The Vitrocell® VC 10 Smoking Robot (Vitrocell® Systems GmbH,
Waldkirch, Germany) is a rotary, single syringe, continuous dilut-
ing ﬂow smoking machine (Fig. 3). The VC 10 Smoking Robot has a
syringe which transfers mainstream cigarette smoke to an inde-
pendent continuous ﬂow dilution system comprising of four or
ﬁve dilution bars. Air is added above and below the dilution bar,
perpendicular to the stream of cigarette smoke and mixes creating
a turbulent stream of diluted cigarette smoke. Smoke dilutions are
created by increasing or decreasing the airﬂow. In addition, a sub-
sample of smoke is drawn from the dilution bar into the module
through negative pressure applied via a vacuum pump.
The VC 10 Smoking Robot is usually paired with the Vitrocell®or CULTEX® exposure modules as their designs are complemen-
tary (Nara et al., 2013). The exposure modules dock directly
under the continuous ﬂow dilution system. Inserts containing cells
are exposed separately to diluted smoke from the dilution bar.
1188 D. Thorne, J. Adamson / Experimental and Toxicologic Pathology 65 (2013) 1183– 1193
Fig. 4. Schematic cross-section of the 3-well mammalian Vitrocell® 6/4 CF Stainless module during exposure. (1) The module lid has specially designed (trumpet) inlets for
optimal aerosol distribution and particle deposition. All smoke inlets dock to the smoke dilution bar during exposure. (2) Integrated with the lid is the aerosol outlet which is
attached to a vacuum pump. (3) The medium is supplied individually for each of the 3 well compartments and does not transit between them. Fresh medium exchange can
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de  performed on a continuous basis per well compartment using a precision mediu
ontrolled water through the module lid and base. The central islands can be unscre
f  particulate deposition.
urthermore, Vitrocell® have developed several exposure module
daptations. For example, there is a mammalian 3 well (Persoz
t al., 2010) and 4 well exposure module for various Transwell®
izes (Fig. 4) and a 24 and 96 well culture plate manifold for higher
hroughput. In addition, Vitrocell® also supply a bacterial exposure
odule for the Ames assay. All exposure modules utilise the same
trumpet’ technology that is shared with CULTEX®, which directs
he exposure aerosol onto the cells, facilitating a more active diffu-
ion and deposition environment within the module.
Okuwa et al. (2010) demonstrated the use of the VC 10 to
ssess the induction of micronuclei in Chinese hamster lung fol-
owing exposure to mainstream cigarette smoke using multiple
moking regimes. In addition, the authors compared the effects
f whole smoke versus vapour phase. Interestingly, Okuwa and
olleagues noted a difference in micronuclei induction for both
moking regimes and also differences between the particulate and
apour phases of mainstream cigarette smoke – indicating that
oth smoke fractions have an importance in micronuclei induc-
ion. Furthermore, the authors used photometer light-scattering
echnology as a real-time measurement tool to semi-quantify
nd monitor smoke delivery, ensuring robust and repeatable
ata.
Like other exposure systems, the VC 10 has its limitations. At
resent there are few scientiﬁc publications on the application of
he VC 10 or on the characterisation of the exposure system itself.
urthermore, the VC 10 has many variables that can be altered to
reate the required exposure set-up, for example: the diluting air-
ow (l/min) and module sampling ﬂow-rate (ml/min/well) can be
djusted independently. This ﬂexibility, although a potential posi-
ive is currently a limitation as the manipulation of these variables
as yet to be fully characterised. However, this is changing and a
ecent study has assessed these variables on particle deposition in
he exposure module. Interestingly, increased module ﬂow-rates
ml/min) had an inverse effect on particulate deposition within the
xposure module (Adamson et al., 2013b).
.5. CULTEX®
CULTEX® Laboratories (Hannover, Germany) offer solutions for
n vitro toxicological analysis of airborne substances, such as gases,
articles, volatile compounds and complex gas mixtures at the
LI. CULTEX® supply in vitro exposure modules which have been
esigned to be used with a variety of exposure systems andp. Constant temperature of the unit is assured by a regulated ﬂow of temperature
o allow the incorporation of the quartz crystal microbalance (QCM), for assessment
aerosols, making them adaptable and applicable to a multitude
of exposure scenarios. As a result, CULTEX® play an active role
in research surrounding in vitro aerosol exposure and inhalation
toxicology.
Over the last decade, the CULTEX® exposure modules have
been used in studies to assess a multitude of complex aerosols,
such as diesel exhaust, cigarette smoke, therapeutics, volatile com-
pounds, particles and environmental pollutants (Aufderheide and
Mohr, 1999, 2000, 2004; Ritter et al., 2001, 2003; Aufderheide and
Gressmann, 2007; Aufderheide et al., 2011; Deschl et al., 2011).
The diversity of these studies demonstrates the scale and potential
application of the CULTEX® exposure modules.
Aufderheide and colleagues ﬁrst introduced the concept of the
CULTEX® exposure module in 1999 and 2000. In the ﬁrst two
publications the authors outlined the use of the CULTEX® exposure
modules for the in vitro assessment of inhalable test compounds
(particles, mineral ﬁbres and wood dust) at the ALI. In 2001, Rit-
ter et al., used test synthetic air, ozone (202–510 ppb) and nitrogen
dioxide (75–1200 ppb) to characterise exposure conditions within
the CULTEX® module, indicating that this module can support a
variety of approaches in the ﬁeld of environmental toxicology for
airborne chemicals. Further characterisation of the CULTEX® mod-
ule was carried out by Aufderheide et al. (2003) who assessed
particulate deposition using a ﬂuorescence spectrophotometer
technique, viability and cellular glutathione levels following expo-
sure to tobacco smoke.
In 2007, Olivera et al., published on epithelial tight junction
permeability using a CULTEX® module, in response to mainstream
cigarette smoke. Using this in vitro exposure system they deduced
a possible mechanism for loss of tight junction stability seen in
respiratory epithelium in smokers.
More recently, Deschl et al. (2011) used the CULTEX® mod-
ule combined with therapeutic aerosols to assess biological
effects. The authors demonstrated that this exposure system can
be used to understand disease mechanisms and as a tool to
assess therapeutic efﬁcacies in vitro, thus potentially reducing
the need for in vivo experimentation in the future. Addition-
ally, the authors noted that the linear arrangement of the
aerosol sampling points along the exposure module gave varying
results within the module, which could be caused by poten-
tial a potential turbulent mixing inefﬁciency and the linear
arrangement of the sampling ports form the dilution system.
The authors also commented that future iterations of this
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echnology may  eliminate any potential limitations and uncertain-
ies (Deschl et al., 2011).
The latest development from CULTEX® is the radial ﬂow sys-
em (RFS) which allows culture medium to be precisely controlled
Fig. 5). The radial arrangement of cell culture inserts around a
entral gas inlet provides homogenous distribution (Aufderheide
t al., 2011). The RFS utilises ‘trumpet’ technology which facilitates
elivery of the aerosol almost directly onto the cell monolayer.
sing the RFS, Aufderheide et al. (2011) demonstrated cytotoxic
esponses in human bronchial epithelial 16HBE cells following
xposure to cigarette smoke. Furthermore, the authors used the
FS for the assessment of revertant colonies using the Ames test
Salmonella typhimurium strains TA98 and TA100) following expo-
ure to tobacco smoke. In a more recent study (Aufderheide et al.,
013) the RFS module demonstrated delivery of a uniform test
erosol to the three culture inserts. This information was in part
btained using computational ﬂuid dynamics to acquire greater
nsight into the ﬂow conditions within the RFS module. The RFS
odule fundamentally differs from the linear glass module in that
ulture inserts are arranged symmetrically around a single gas inlet,
hus eliminating any concentration gradient observed potentially
ue to linear sampling points. In addition to delivery of a homoge-
ous test article, the RFS module also allows for the incorporation
f different cell culture inserts and petri-dishes for the Ames assay.
nterestingly, the authors also showed a correlation between par-
icle size and distribution against deposited mass for aerosolised
opper oxide nanoparticles (CuO). For example, direct exposure
f CuO showed increased cytotoxicity in A549 cells compared
o micro-sized particles, suggesting that cells were exposed to a
reater number of smaller sized particles per cm2 area (Aufderheide
t al., 2013).
CULTEX® Laboratories supply a diverse range of exposure cham-
ers for a variety of exposure scenarios and aerosol test compounds.
ULTEX® Laboratories also offer a dust aerosol generating sys-
em, which is comprised of three independent components; a
yP-Hydraulic Press for preparing powder cakes from a variety
f powdery materials, a dust generator (CULTEX® DG) which pro-
ides uniform concentrations of aerosolised dust, and ﬁnally, an
ntegrated elutriator, which stores the dust aerosol, serves as a
eservoir for generated particles and facilitates uniform aerosol
elivery (Aufderheide et al., 2013).
. Dosimetry for smoke exposure
As tobacco smoke is a physically and chemically complex mix-
ure, it is important to understand exactly what components of
moke the cell cultures in smoke exposure systems are being
xposed to. There are plenty of opportunities for the smoke
erosol to coagulate and deposit during transition through whole
moke exposure systems; in addition, deposition efﬁciencies dif-
er between systems. Therefore, exposure concentrations set on
hese smoking machines will not always resemble that of the actual
ellular dose.
Tobacco smoke has two phases which contribute in distinct
ays to lung injury and cellular damage. It is therefore important
rom a dosimetry perspective to understand the characteristics and
nteractions of both of these phases. For the deposited fraction, con-
entration, particle size and mass can be measured with standard
erosol monitoring devices and has previously been documented
Adam et al., 2009; Hofmann et al., 2009). Additionally, several
ecent and comprehensive reviews in the area of aerosol science
nd biology have been conducted (Grass et al., 2010; Paur et al.,
011). In terms of in vitro exposure, especially for those systems
elying on diffusion and/or sedimentation, particle deposition efﬁ-
iency is relatively low, about 16% (Desantes et al., 2006). However,cologic Pathology 65 (2013) 1183– 1193 1189
recent technical developments have seen the use of electrostatic
precipitation to increase experimentally determined overall depo-
sition efﬁciencies under the inﬂuence of an alternating electrostatic
ﬁeld to 15–30% when applied to monodisperse polystyrene parti-
cles in the size range of 50–600 nm (Savi et al., 2008). This allows
researchers to tailor their exposure system to maximise depo-
sition efﬁciency (Bruijne et al., 2009). Electrostatic precipitation
devices are commercially available from CULTEX® (EDD), which
offers the added beneﬁt that they can be used in conjunction and are
compatible CULTEX® exposure modules. Using this system parti-
cle deposition efﬁciency especially for those particles not normally
deposited through sedimentation or diffusion can be increased up
to 95% (Aufderheide et al., 2013).
There are a number of physical, chemical and gravimetric
methods for determining tobacco smoke dosimetry in vitro. Most
techniques have limitations and there is no general consensus on
the most appropriate approach to quantifying dose. Some tech-
niques look at speciﬁc tobacco smoke markers such as solanesol
in the particulate phase, or carbon monoxide in the gas phase,
whilst others quantify smoke in larger groups/families of chem-
icals. The majority of dosimetry techniques and measurements
are based on the particulate phase of cigarette smoke, mainly
due to the challenges associated with measuring vapour phase
markers. Attempts have been made to use more sophisticated tech-
niques for vapour phase analysis. In 2011, Kaur et al., described
a headspace stir bar-sorptive extraction GC–MS technique for
the assessment of cigarette smoke vapour phase compounds
(volatile and semi-volatile compounds) including; 2-methyl-
1,3-butadiene, 3-methyl-2-butanone, benzene, 2,5-dimethylfuran,
toluene, ethylbenzene, p-xylene, styrene, 1-methy-4-(methyl-
ethylidene)cyclohexane and limonene during in vitro exposure.
Such techniques may  not allow for real-time analysis, but may
provide answers as to the relationship between smoke constituents
and dose. In addition these tools may also be applied in a cross-
platform approach.
The development of dosimetry tools to measure the vapour
phase of tobacco smoke in vitro is a massive challenge (Lin et al.,
2012). Currently, there is a trend to measure the particulate phase
of tobacco smoke within these exposure system. In the following
sections, a variety of available dose tools for particulate and vapour
are discussed in more detail.
3.1. Deposition assessment using ﬂuorometric analysis
One method for the quantiﬁcation of particulate deposition is
chemical spectroﬂuorometric analysis (Ritter et al., 2003). In brief,
pre-wetted cell culture inserts housed within the exposure cham-
ber are exposed to whole mainstream smoke. Deposited particulate
material can be extracted using high performance liquid chro-
matography (HPLC) grade methanol and agitation, and extracts
analysed with HPLC and ﬂuorescence detection with standard cali-
bration curves (Adamson et al., 2011, 2012). This method, although
not real-time, offers a simplistic approach to quantifying dose
and has been used in a variety of studies. The advantage of this
wet-chemistry technique is it can be applied to any exposure sys-
tem/exposure chamber format (small well plates up to Petri-dishes)
and results should be relatively consistent and comparable across
laboratories.
3.2. Light scattering photometers
Photometers are designed to perform in-line measurements of
the particle droplet suspended in the gas (termed optical tar) via
a light scattering optical sensor. They are capable of measuring
optical density at very low ﬂow rates without any losses to the
particle mass. Photometer technology has been around for many
1190 D. Thorne, J. Adamson / Experimental and Toxicologic Pathology 65 (2013) 1183– 1193
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cig. 5. CULTEX® – radial ﬂow system (RFS) in three stages of opening to insert cell
ultured on Transwell® membranes are housed. (C) Media inlets and outlets for pre
ears and has been used in a variety of studies, both in vivo and in
itro (Bellmann et al., 2009; Okuwa et al., 2010). The technology
e speciﬁcally refer to here is a condensed portable version that
an be incorporated into any aerosol exposure system for the direct
nalysis of aerosol density without effecting the aerosol stream.
ue to its size and versatility, photometer technology can offer
any advantages to an in vitro exposure system. Okuwa et al.
2010) demonstrated this by publishing data using portable pho-
ometers (Vitrocell® Systems, Waldkirch, Germany) in-line as a
eal-time monitoring tool. In this system the authors were able
o monitor and quantify the amount of cigarette smoke particu-
ate matter entering the chamber during exposure in real-time.
his information is invaluable in ensuring the exposure conditions
re both consistent and reproducible. Photometer technology does
ave its limitations. One such limitation is that these photometers
ave to be precisely calibrated against a known particulate mass;
urthermore, in-line particulate measurements do not always
esemble (although may  give an indication of) deposited mass at
he ALI.
.3. Quartz crystal microbalance
Quartz crystal microbalance (QCM) technology has also been
round for many years and has been successfully used to quan-
ify several types of engineered nanoparticles (Koesslinger and
rost, 1998; Uttenthaler et al., 1998, 2001; O’Sullivan and Guilbault,
999; Klepeis et al., 2007). The QCM works via the piezoelec-
ric effect and is capable of measuring and detecting changes in
ass within the nanogram range (Mülhopt et al., 2009). QCMs
ave a working detection range for particle sizes between 150
nd 500 nm (Desantes et al., 2006), which closely resembles the
ange for tobacco smoke particles (150–200 nm)  making this tech-
ology ideal for the assessment of deposited tobacco particulate
ass.
Recently and for the ﬁrst time QCMs have been used to inves-
igate the deposition of tobacco smoke particle mass in vitro. In
act, QCMs have been incorporated into several in vitro exposure
hambers to assess real-time deposition uniformity/gradients and
or quality control purposes (Adamson et al., 2012, 2013a,b). This
s the ﬁrst time that a dose tool has been able to measure deposited
ass in real-time, in situ of exposure. Such a tool offers researchers
he opportunities to investigate deposition data from a variety of
igarettes and potentially control exposure based on particulateres grown on porous membranes. (A) Aerosol guiding unit. (B) Module where cells
ontrol of media ﬂow. (D) Chamber base with lock.
dose, simulating that of in vivo exposure. This in turn would
make both the in vivo and in vitro data much more compara-
ble. In a study presented by Adamson et al., in 2012 the authors
accurately correlated deposition data from HPLC techniques and
QCMs (R2 = 97.4%) demonstrating that these tools/methods can be
used interchangeably. In a later study using QCMs, Adamson et al.
(2013b) demonstrated the effect of airﬂow (l/min) on particle depo-
sition in the Vitrocell® 6/4 CF Stainless module.
Irrespective of the exposure system, QCM tools offer researchers
a consistent approach with an associated gravimetric unit of
deposited mass per surface area (g/cm2) that can be used to
express in vitro data allowing more accurate comparisons between
data from various systems to be made.
3.4. Vapour phase
Carbon monoxide, carbon dioxide and nitrogen oxides (CO, CO2
and NOx) are simple components of the complex vapour phase of
tobacco smoke and due to their facile quantiﬁcation by infrared gas
analysers, make ideal smoke markers. Vapour phase markers can
be quantiﬁed in-line or remotely, but both techniques have limi-
tations. In-line quantiﬁcation has the beneﬁt of being in real-time;
however it can only be applied to one smoke position/line (unless
using more than one analyser). In addition, the analyser’s ﬂow rate
may  affect the smoke transit, altering results. Furthermore, actual
concentrations appear as concentration peaks with every smoke
puff, thus a mean exposure concentration over time must be calcu-
lated (Ritter et al., 2004). Alternatively, connecting smoke outlets
to gas collection bags (Douglas bags) has the beneﬁt that each line
can be read after the smoke run. Furthermore, the gas being ana-
lysed is the total concentration amassed over the duration of the
run, in a homogenous mixture. However, the duration of the smoke
exposure run may  need to be reduced signiﬁcantly in order to pre-
vent overﬁlling of the bag, in some cases high ﬂow rates may  not
be possible at all.
More recently, Nara et al. (2013) demonstrated the ability to
quantify carbonyls in tobacco smoke using a carbonyl DNPH (dini-
trophenylhydrazine) trap and HPLC technique. Analysis of vapour
phase components using chemistry trapping set-ups may  provide
the key in characterising vapour phase dilution and delivery within
these systems. The vapour phase of smoke within these systems
remains poorly understood considering it is the majority smoke
fraction.
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. Discussion
For tobacco smoke generation, dilution and delivery in vitro,
here are various commercial and bespoke whole smoke options
vailable. These exposure technologies ensure that there are
imited changes in the tobacco smoke material during collection,
ilution, transit and delivery (Okuwa et al., 2010). Of the commer-
ial systems available some have been characterised more than
thers in terms of published scientiﬁc literature and developed bio-
ogical endpoints. Others are relatively new to the scientiﬁc ﬁeld
nd are still establishing their presence. The Borgwaldt RM20S
nd associated exposure chamber have been almost exclusively
sed by British American Tobacco. The CULTEX® exposure mod-
les have been used to assess a variety of airborne chemicals and
re not limited to tobacco smoke. The Burghart Mimic  Smoker
SB-01 offers a more high throughput based exposure, but cells
re not exposed at the ALI which ultimately limits the use of this
echnology. The Vitrocell® VC 10 Smoking Robot has not been
haracterised to the extent of other systems, with very little infor-
ation existing in the scientiﬁc domain, although this appears to be
hanging. Bespoke systems are also widely used for whole smoke
xposure, but vary in smoke generation, dilution and exposure
rinciples, that make comparison of these technologies difﬁcult.
hat is clear is that they have a place in fundamental and mecha-
istic research. However, for a consistent approach these systems
ay  be too unique in their individual development to be widely
sed. As yet, no exposure system commercially available or oth-
rwise has been completely characterised or validated and each
ystem offers unique advantages and disadvantages. Interestingly,
n assessment of different whole smoke exposure technologies by
he Cooperation Centre for Scientiﬁc Research Relative to Tobacco
CORESTA) – a tobacco related in vitro task force, found remarkably
onsistent results, indicating these systems perform in a similar
ay (CORESTA air–liquid interface report). For example, reported
osses in both the Burghart Mimic  Smoker MSB-01 and Borgwaldt
M20S are similar at 40–50% (Scian et al., 2009a; Adamson et al.,
011). This is interesting considering these two set-ups are diverse
rom each other. What is clear, is that whole smoke exposure
ystems are an important development for the delivery of a physi-
logically relevant test smoke aerosol in vitro (Johnson et al., 2009).
n support of this, in June 2009 the Committee on Mutagenicity in
he UK reviewed the area of ‘chemicals in foods, consumer prod-
cts and the environment’ and commented that the development
f whole smoke exposure procedures were likely to provide more
elevant data on the mutagenic activity of tobacco smoke, but
oted none of the test systems had been “adequately validated”
Committee on Mutagenicity, 2009). Validation remains an obvi-
us area for improvement in this ﬁeld of research and as yet no one
as conducted a multi-laboratory or multi-system study.
The scientiﬁc literature surrounding whole smoke in vitro sys-
ems has demonstrated a wealth of associated biological endpoints,
isease and toxicological. For example, tobacco smoke in vitro has
een shown to induce a variety of cellular effects potentially asso-
iated with disease processes, which include the up-regulation
f a series of factors linked to lung damage and inﬂammation,
issue remodelling, mucin overproduction and cellular transforma-
ion (Leikauf et al., 2002; Breheny et al., 2005; Heeg et al., 2006;
livera et al., 2007; Newland and Richter, 2008; Haswell et al.,
010). Tobacco smoke has also been shown to generate high lev-
ls of reactive oxygen species and oxidative stress which can cause
ellular damage to lipids, proteins and DNA (Chow, 1993; Cooke
t al., 2003; Federico et al., 2007). In addition, tobacco smoke has
een shown to have multiple effects on gene expression in the
uman airways. Studies of bronchial epithelial cells obtained from
he airways of smokers and non-smokers by bronchial brushing
as indicated that cigarette smoke induces metabolising and redoxcologic Pathology 65 (2013) 1183– 1193 1191
regulating genes, tumour suppressor genes and oncogenes along-
side the regulation of inﬂammatory processes (Brody and Steiling,
2011; Hackett et al., 2011). Cellular glutathione response to tobacco
smoke has also been extensively documented in in vitro and in vivo
studies. The glutathione redox system is critical in maintaining
intracellular glutathione levels, which are important to normal cel-
lular physiological processes and antioxidant defence systems in
the lung. If cellular glutathione levels are signiﬁcantly altered a vari-
ety of cellular processes are initiated, such as the activation of the
transcription factors AP-1 and Nuclear Factor kappa , which can
lead to the activation of a variety of disease pathways (Rahman and
MacNee, 1999). In terms of in vitro test method development this is
a promising sign, indicating that these systems have the potential
to support and supplement a variety of future exposure scenarios.
5. Conclusions
The amount of smoke delivered to cells within in vitro exposure
systems can be presented in many ways, often dependent upon the
machine used, either as a ratio of smoke to air, or as a ﬂow rate
of mixing air applied to the smoke dilutor, or as a percentage or a
smoke fraction. However, what is more relevant and is becoming
increasingly important in the ﬁeld of tobacco smoke assessment
in vitro is dosimetry: i.e. how to quantify the amount of smoke cells
are directly exposed to. At present there is no recognised approach
to the measurement of dose, and the vapour phase of cigarette
smoke within these systems remains poorly understood. With the
variety of exposure options available to researchers and bespoke
systems relatively easy to fabricate or replicate, dosimetry tools
may  bridge the gap and play an important role, not only in the
measurement of actual cellular dose but also in the characterisa-
tion and validation of these systems. Furthermore, utilising dose
tools such as the QCM in real-time will give conﬁdence that the
related exposure system is operating within expected limits, allow
researchers to monitor exposure conditions, add strength to the
resulting in vitro data, and allow cross-platform comparisons to be
made where currently they cannot.
Advances in exposure technologies have allowed investigators
to study some of the underlying mechanisms of tobacco induced
cellular injury and ultimately disease mechanisms. Furthermore, a
plethora of in vitro models have been developed alongside these
exposure systems that may  be used when assessing the biologi-
cal activity of tobacco smoke. In terms of understanding tobacco
smoke and disease, elucidating disease mechanisms and identify-
ing smoke toxicants responsible for adverse health effects, in vitro
methods will be key, providing the related exposure system is accu-
rately characterised.
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